Traditional specialty drugs for diseases such as rheumatoid arthritis and multiple sclerosis are best served under an open distribution model where...
Before any anticipated specialty drug launch, a pharmaceutical manufacturer conducts an extensive market access evaluation to determine the best...
On Rare Disease Day, we are dedicating this blog to Tommy, a selfless and caring individual we had the opportunity to serve for several years. In 2003,...
Rare Disease Day is an observance to help raise awareness for the 300 million people living with rare diseases worldwide. For Orsini, it is a day to...
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has earned URAC’s prestigious...
According to the National Institutes of Health (NIH), approximately 7,000 rare diseases affect between 25 and 30 million Americans (almost 1 in 10)1....
Almost 1 in 10 Americans are affected by a rare disease.1 Common challenges rare disease patients face include limited treatment options, little to no...
Tardive Dyskinesia (TD) is a neurological movement disorder typically characterized by repetitive, involuntary movements of the jaw, lips, and tongue....
Orsini Specialty Pharmacy, a leading independent specialty pharmacy focused on rare diseases and gene therapies, has been selected by Provention Bio,...
Mucopolysaccharidosis (MPS) is an inherited metabolic disease in which the body does not produce enough enzymes to break down sugars into simpler...
Orsini is a leading independent national specialty pharmacy accredited by ACHC, JCAHO, URAC, and VIPPS. The services we provide allow patients, physicians, payors, and manufacturers to improve care, simplify processes, and achieve better outcomes.
Orsini Specialty Pharmacy Names Darin DeCarlo Chief Growth Officer
Orsini Specialty Pharmacy Selected to be the Exclusive Specialty Pharmacy Partner for VEOPOZ™ (pozelimab-bbfg), the First and Only Treatment for CHAPLE Disease
Orsini Selected by BioMarin to Dispense ROCTAVIAN™, the First Gene Therapy for the Treatment of Severe Hemophilia A
Optimizing Patient Care Services with Rare Disease Limited Distribution Drugs
Orsini Selected by Sarepta Therapeutics to Dispense ELEVIDYS (delandistrogene moxeparvovec-rokl), the First Gene Therapy to Treat Duchenne Muscular Dystrophy
.jpg?width=1754&height=637&name=SP_Logo_Color_RGB%202020update%20(1).jpg "Orsini Specialty Pharmacy Logo"){kind=logo}
![[Whitepaper] Payor Considerations When Choosing a Specialty Pharmacy](https://no-cache.hubspot.com/cta/default/7642930/d6329582-47a1-404d-b2a8-63c2637a9807.png)